In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh